Antiproteinuric effect of ciclosporin A in adriamycin nephropathy in rats by Desassis, J.F. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/25145
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
NEPHRON
.ƒ. F. Desassis 
C.J.I. Raals
MA.H. Bakker 
J. van den Bom 
J.H.M. Berden
Division of Nephrology,
St. Radboud U niversity Hospital, 
Nijmegen, The Netherlands
Abstract
Ciclosporin A (CsA) can reduce proteinuria in various forms of human and 
experimental glomerulopathies. This antiproteinuric effect can be the result of 
a decrease of immunological damage, a decrease in the glomerular filtration 
rate (GFR), or a change in the permselective properties of the glomerular cap­
illary wall. In this study we investigated the effect of CsA on Adriamycin- 
induced nephropathy in rats. A single intravenous injection of Adriamycin 
(5 mg/kg body weight) induced a severe nephrotic syndrome with a massive 
albuminuria (±  400 mg/24 h from 3 weeks onwards) and a hypoalbuminemia 
( ± 7  mg/ml after 5 weeks). The IgG/albumin selectivity index was 0.16 ±
0.05, indicating a preferential loss of albumin. A 5-day treatment with CsA 
reduced the albumin excretion by almost 50% (from 336 ±  91 to 178 ± 58 
mg/24 h; p = 0.002) and induced an increase in the serum albumin level (from 
7,1 ± 4.1 to 12.8 ± 3.2 mg/ml; p = 0.002) in contrast to the vehicle olive oil 
(OO). CsA also decreased the GFR by 40% (from 0.74 ± 0.11 to 0.41 ±0.11 
mg/ml/100 g body weight; p = 0.002). Albuminuria corrected for the GFR 
(fractional excretion of albumin, FEaib) was still significantly lower in CsA- 
treated than in OO-treated animals (FEaib CsA: 1.35 ± 0.88, FEaib OO: 3.17 ± 
2.29%; p = 0.0005). This suggests that other factors are also involved in the 
reduction of albuminuria. To exclude that CsA has an effect on the tubular 
reabsorption of albumin, we evaluated the blockade of the tubular reabsorp­
tion by lysine and found no difference in albuminuria between the CsA- and 
OO-treated groups. These experiments suggest that the antiproteinuric effect 
of CsA is not (only) due to a decrease in the GFR, but also to a decrease of the 
enhanced permeability of the glomerular capillary wall for albumin.
»
models [1, 2]. As CsA is a potent immunosuppressive 
drug, it is possible that this antiproteinuric effect is due to 
inhibition of the glomerular inflammatory process. How­
ever, although the immunosuppressive effect might con­
tribute to the observed antiproteinuric effect, there are
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Introduction
The antiproteinuric effect o f ciclosporin A (CsA) has 
been described in several studies, both in patients with 
various glomerular diseases and in experimental animal
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several arguments which indicate that other mechanisms 
are also involved, since CsA is also effective in nonim- 
mune glomerular diseases like Alport syndrome [3]. The 
antiproteinuric effect of CsA could be due to the drug- 
induced reduction of the glomerular filtration rate (GFR), 
which leads to a decrease of the filtered load of protein. If 
this mechanism is responsible, the fractional excretion of 
albumin (FEaib) should be identical before and after treat­
ment. However, as we [4, 5] and others [3, 6] have shown, 
the FEaib was significantly lower during CsA treatment, 
which suggests that the reduction in GFR is not solely 
responsible for the observed antiproteinuric effect. Fur­
thermore, in patients with focal glomerulosclerosis and 
membranoproliferative glomerulonephritis, CsA induced 
a significant drop in GFR and effective renal plasma flow, 
but had no effect on proteinuria [6]. This discrepancy 
between the hemodynamic and antiproteinuric effects of 
CsA raises the possibility that CsA may influence the 
permselective properties of the glomerular capillary wall 
(GCW). Recently, we did indeed find in a passive model 
of murine anti-glomerular basement membrane nephritis 
that CsA still had an antiproteinuric effect after pharma­
cological prevention with phenoxybenzamine of the CsA- 
induced drop of the GFR [4]. This study underlines that 
the antiproteinuric effect of CsA might be due to mecha­
nisms other than GFR reduction. The results of in vitro 
glomerular permeability studies also show an effect of 
CsA. Isolated glomeruli of animals treated with CsA for 
2-3 weeks [7] or glomeruli exposed to CsA in vitro [8] 
displayed in vitro a significantly lower ultrafiltration coef­
ficient Kf and a lower hydraulic conductivity Lp than con­
trol glomeruli. Theoretically, CsA could increase the tubu­
lar reabsorption of albumin, although this explanation is 
not very likely in the face of the known tubulotoxic effects 
of CsA.
One of the most widely accepted indications for CsA 
treatment in the nephrotic syndrome is minimal change 
disease (MCD). Proteinuria decreases after the introduc­
tion of CsA in the majority of patients with MCD [9-12]. 
It has been argued that CsA may be effective in MCD by 
inhibiting the production of certain cytokines [9] or circu­
lating cations [13] which are thought to be responsible for 
disturbing the charge-selective permeability of the GCW. 
We decided to study the antiproteinuric effect of CsA in 
Adriamycin nephropathy (ADR-NP). Because of the dis­
appearance of the glomerular polyanion, ADR-NP is, 
although not uniformly, regarded as an experimental 
model of MCD [14,15]. A second argument to study CsA 
in ADR-NP is that this experimental model has a nonim- 
munological genesis. This circumvents possible effects of
CsA on the evolution of the nephrotic syndrome. In this 
model we investigated in animals with a heavy and stable 
proteinuria the antiproteinuric effect of CsA, and we cor­
related this with the CsA-induced changes in GFR. To 
exclude the possibility that CsA influences the tubular 
reabsorption of albumin, we analyzed the effect of intra­
venously administered lysine on the albumin excretion in 
CsA-treated and control rats.
Materials and Methods
Animals
For all experiments we used male Wistar rats that were bred in 
our animal laboratory and weighed ±  200 g at the start of the experi­
ments. The animals were fed standard food and tap water ad libi­
tum.
Adriamycin Nephropathy
Adriamycin® (Adriablastina; Farmitalia, Milan, Italy) was ad­
ministered as a single intravenous injection via the tail vein under 
ether anesthesia. In an initial experiment, the optimal dose of ADR 
was determined. To this end, either 2.5, 5, or 7.5 mg ADR/kg body 
weight (BW) was injected into 5 rats/group. This experiment re­
vealed that with 5 or 7,5 mg ADR/kg BW a stable albuminuria was 
achieved 3 weeks after the injection, whereas after 2,5 mg/kg the 
ensuing albuminuria was less severe and still increasing after 3 
weeks. Since a dose of 5 mg/kg was not associated with any direct 
morbidity or mortality, in contrast to the 7.5 mg/kg dose, the 5 mg/kg 
dose was adopted for all further experiments.
Urine and serum samples were collected every week for 5 weeks 
to determine albumin and IgG concentrations. Urinary protein 
excretion was measured in urine collected for 24 h in metabolic 
cages. Urine and serum concentrations of albumin were determined 
by rocket immunoelectrophoresis [16], with goat anti-rat albumin 
and rat albumin as a standard (both from Nordic, Tilburg, The Neth­
erlands). Urine and serum IgG concentrations were determined by 
means of a capture ELISA as previously described [17]. From these 
data, the albumin clearance and the FEaib (clearance of albumin/ 
GFR) were calculated with standard formulas. The selectivity index 
of the proteinuria was calculated as clearance IgG/clearance albu­
min.
CsA Treatment
To assess the antiproteinuric effect of CsA (Sandoz Nederland, 
Uden, The Netherlands), rats injected with 5 mg/kg BW ADR on day 
0 received either CsA (n = 10) or the solvent olive oil ( 0 0 ;  n = 10). 
CsA was orally administered once daily at a dose of 20 mg/kg BW in 
0.5 ml OO. On day 28, 24-hour urine was collected, a serum sample 
was drawn, and the GFR (see below) was measured on day 29. There­
after, CsA or OO treatment was started on day 30. During CsA treat­
ment, urinary protein excretion was determined on day 34 and GFR 
on day 35. At the end of the experiment, the animals were sacri­
ficed.
GFR was measured by the single-shot 51Cr-EDTA technique. In 
brief, after an intravenous injection of 10 jiCi 51Cr-EDTA (Amers- 
ham, UK), a single timed (60 min) blood sample was obtained from 
the retro-orbital plexus under ether anesthesia. A calibrated 200-jil
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Fig. 1. Serum albumin and albuminuria over time in rats after a 
single intravenous injection of 5 mg ADR/kg BW, O = Serum albu­
min; •  = urinary albumin excretion.
plasma sample was counted in a gamma scintillation counter. GFR 
was calculated according to the formula: GFR = (V/t)*ln(P0/Pt), 
where V is the distribution volume of 51Cr-EDTA (ml) and PO, Pt the 
plasma concentration of 51Cr-EDTA at time zero and t min (cpm/ 
ml). Pt is derived from the plasma sample at t = 60 min; PO is calcu­
lated from PO = I/V, where I is the injected amount of 5lCr-EDTA 
(cpm), and V is calculated from the formula established by Provoost 
at al. [18]: Y = (0.264-BW) -  (1.92• 10-4 BW2) + it03i
To evaluate the effect of CsA on the tubular reabsorption of albu­
min, the effect of an intravenous bolus injection of lysine was investi­
gated in a different group of animals. To this end, CsA or OO treat­
ment (n = 10 for each group) was started on day 30 after injection of 
ADR and continued daily until the end of the experiment (day 36). 
On day 34 GFR was measured. On day 35 urinary albumin excretion 
was measured during 2 h, thereafter the animals received 600 mg/ 
100 gBW lysine, and urinary albumin excretion was measured again 
for 2 h. To evaluate the effect of lysine on GFR, the next day the 
same dose of lysine and immediately thereafter 5,Cr-EDTA were 
administered to measure GFR.
Statistics
The Mann-Whitney U test was used for intergroup comparisons, 
and the Wilcoxon signed-rank test was used for intragroup compari­
sons. p <5%  was considered significant.
Results
Characteristics o f  ADR-NP
After an intravenous injection of 5 mg/kg BW ADR, a 
progressive albuminuria developed from 7 days onwards 
after the injection. At 3 weeks, this urinary albumin excre­
tion stabilized at around 400 mg/24 h and thereafter 
remained at that level (fig. 1). Concomitant with the 
increase in urinary albumin excretion, there was a severe
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drop in serum albumin levels, reaching 5-7 mg/ml at 5 
weeks. Despite this severe decrease in serum albumin 
concentration, there was an increasing clearance of albu­
min. To investigate whether this proteinuria was se­
lective, we calculated the selectivity index of the protein­
uria (clearance of IgG/clearance of albumin) at week 4. 
This revealed a selectivity index of 0.16 ± 0.05(95%con- 
fidence interval 0.14-0.18), indicating a preferential uri­
nary loss of albumin.
Antiproteinuric Effects o f  CsA
Treatment with CsA in the ADR model resulted in a 
significant decrease of albuminuria and an increase of 
serum albumin, in contrast to the OO-treated controls, in 
which these two parameters did not change (table 1). As 
expected, the GFR also decreased significantly in the 
CsA-treated animals, whereas in the OO-treated group the 
GFR remained stable. However, the increase in serum 
albumin together with the reduction in GFR cannot 
explain the reduction in albuminuria. When we calcu­
lated the albuminuria corrected for serum albumin and 
GFR (FEaib), we still observed a significant decrease in the 
CsA-treated animals, whereas this parameter did not 
change in the OO-treated controls (table 1). If the GFR 
reduction was not (solely) responsible for the decrease in 
albuminuria, theoretically two other major mechanisms 
could be responsible for the antialbuminuric effect. CsA 
could either decrease the enhanced permeability of the 
GCW for proteins or increase the tubular reabsorption of 
albumin. Although this enhanced tubular reabsorption is 
unlikely in view of the known tubulotoxic effect of CsA,
Desassis/Raats/Bakker/van den Bom/ 
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Table 1 - Effect of CsA or OO on albuminuria, serum albumin, GFR, and FEaib in rats with ADR-NP
CsA OO
Albuminuria, mg/24 h 
Serum albumin, mg/ml 
GFR, ml/min/lOOgBW 
FEaib, %
before
336±91 
7.1 ±4.1 
0.74 ±  0,11 
2.43+1.26
after
178±58 
12.8 ±  3.2 
0 .41±0.11 
1.35 + 0.88
P
0.002
0.002
0.002
0.002
before
389 ± 123 
5.5±2.1 
0 .7 0 ± 0 .12 
4 .06± 3.29
after
311 ±46  
5.6±2.7 
0.73±0.12 
3.17±2.29
P
NS
NS
NS
NS
NS = Not significant.
we wanted to formally exclude this possibility. Therefore, 
we investigated whether the effect of blockade of the tubu­
lar albumin reabsorption by lysine differed between the 
two groups. We found no significant difference in the 
absolute amount of urinary albumin excretion before and 
after lysine infusion in both groups (table 2). However, 
lysine induced both in the CsA- and the OO-treated ani­
mals a significant decrease in the GFR and thereby in the 
filtered load of albumin. This lysine-induced decrease in 
GFR was also seen in control rats (table 2). Therefore, we 
calculated the ratio between the 2-hour excretion of albu- 
min/GFR before and after lysine administration, assum­
ing that the serum albumin concentration did not change 
during this short observation period. In CsA-treated ani­
mals, this ratio was 1.5 ±  0.6 and in the OO-treated rats
1.8 ± 0.9. From these ratios it is clear that lysine induced 
in both groups a significant increase of the FEaib due to a 
blockade of tubular albumin reabsorption. This increase 
in the FEaib was not statistically different between the two 
groups (p = 0.6).
Table 2. Effect of lysine on albuminuria, GFR, and albuminuria/ 
GFR ratio in ADR-NP in rats treated with either CsA or OO
Lysine
before after P
CsA
Albuminuria, mg/2 h 1 i .2 ± 3 .9 11.3 +  3.0 NS
GFR, ml/min 0.89 ±0,20 0.64+0.20 0.012
Albuminuria/GFR ratio 13.3 +  4.9 20.0±3.8 0.03
Albumin uria/GFR ratio
after/before lysine 1.5±0,6
OO
Albuminuria, mg/2 h 15.9 +  7.1 19.9 ±  5.3 NS
GFR, ml/min 1.44±0.35 1.22 + 0.28 0.008
Albuminuria/GFR ratio 1L5 +  5.0 17.0±4.7 0.06
Albuminuria/GFR ratio
after/before lysine 1.8±0.9 ~ a
Control rats
GFR, ml/min 2.14 + 0.16 1.94 + 0.05 0.012
NS -  Not significant.
11 The ratio between CsA and OO is not significantly different.
Discussion
In this study, we investigated the effect of CsA on 
ADR-NP which is regarded as a model for human MCD. 
The injection of 5 mg ADR/kg BW in rats induced a 
severe nephrotic syndrome with a massive albuminuria 
and an evident hypalbuminemia which was also found in 
previous studies [14, 15]. In the literature several contra­
dictory mechanisms have been proposed for the induction 
of this ADR-associated nephrotic syndrome, either a de­
crease in the charge-dependent permeability [14, 19, 20] 
or an increase of the size-dependent permeability of the 
GCW [ 15,21 ] or a combination of both mechanisms [22]. 
In our study, we found a rather selective proteinuria
which is more in line with a charge-dependent alteration. 
This is corroborated by our finding that the heparan sul­
fate staining of the glomerular basement membrane de­
creases by 60% over a period of 4 weeks, as we described 
previously [23]. With different but less specific ap­
proaches, a reduced glomerular polyanion has been found 
in ADR-NP before. In the first detailed description of 
ADR-NP [14], it was already reported that with the use 
of colloidal iron the glomerular polyanion disappeared 
quickly and was totally absent for at least 4 weeks. With 
polyethyleneimine as a probe, a 25% reduction in the 
number of heparan sulfate-associated sites was found in
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the lamina rara externa of rats with ADR-NP [24], and 
with cationic colloidal gold a 60% reduction of anionic 
sites in the GBM of rats with ADR-NP was observed [25]. 
Benjelloun et al. [26] found a reduced number of total gly- 
cosaminoglycans in the glomeruli and an increased uri­
nary excretion of both total glycosaminoglycans and of 
heparan sulfate. Since heparan sulfate is not only a deter­
minant for the charge-dependent permeability, but also 
for the size-dependent permeability [27], these alterations 
might explain the existing discrepancies with regard to the 
pathophysiology of proteinuria in ADR-NP. To investi­
gate whether other mechanism than the GFR reduction 
were responsible for the antiproteinuric effect of CsA, we 
evaluated the effect of blockade of the tubular albumin 
reabsorption by lysine. We found a similar change in albu­
minuria after lysine treatment between the CsA- and 0 0 -  
treated groups. Although the GFR decreased, there was 
no difference in the ratio of the 2-hour excretion of albu­
min before and after treatment with lysine between the 
CsA- and OO-treated groups. Therefore, we were able to 
exclude that CsA has its effect through a change in tubular 
reabsorption of albumin.
These experiments suggest that the antiproteinuric ef­
fect of CsA is not (only) due to a decrease in the GFR, but 
also to a decrease of the enhanced permeability of the 
GCW for proteins. How can one envision this effect of
CsA on the glomerular permeability? It is known that 
ADR can induce the formation of reactive oxygen species 
[28]. Indeed, in ADR-NP, the glomerular cells produce 
reactive oxygen species which cause glomerular injury, 
leading to proteinuria [29]. Also in other experimental 
models, such as Heymann nephritis and puromycin ami- 
nonucleoside-induced nephrosis, it is established that the 
proteinuria critically depends on the formation of reac­
tive oxygen species [30-32]. The normalization of the glo­
merular permeability might be due to the fact that CsA is 
able to inhibit formation of reactive oxygen species [33].
In conclusion, our study suggests that the antiprotein­
uric effect of CsA in ADR-NP is due to both a decrease in 
GFR and a reduction of the enhanced permeability of the 
GCW for albumin.
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